Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty

Ernest Tambo1,2,3,4*, Emad I. M. Khater5,6, Jun-Hu Chen7,8,9, Robert Bergquist10 and Xiao-Nong Zhou5,6,7*

Abstract

The Millennium Development Goals (MDGs) made a marked transformation for neglected and vulnerable communities in the developing countries from the start, but infectious diseases of poverty (IDoPs) continue to inflict a disproportionate global public health burden with associated consequences, thereby contributing to the vicious cycle of poverty and inequity. However, the effectiveness and large-scale coverage of artemisinin combination therapy (ACT) have revolutionized malaria treatment just as the control of lymphatic filariasis (LF) and onchocerciasis have benefitted from harnessing the broad-spectrum effect of avermectin-based derivatives. The paradigm shift in therapeutic approach, effected by these two drugs and their impact on community-based interventions of parasitic diseases plaguing the endemic low- and middle-income countries (LIMCs), led to the Nobel Prize in Physiology or Medicine in 2015. However, the story would not be complete without mentioning praziquantel. The huge contribution of this drug in modernizing the control of schistosomiasis and also some intestinal helminth infections had already shifted the focus from control to potential elimination of this disease. Together, these new drugs have provided humankind with powerful new tools for the alleviation of infectious diseases that humans have lived with since time immemorial. These drugs all have broad-spectrum effects, yet they are very safe and can even be packaged together in various combinations. The strong effect on so many of the great infectious scourges in the developing countries has not only had a remarkable influence on many endemic diseases, but also contributed to improving the cost structure of healthcare. Significant benefits include improved quality of preventive and curative medicine, promotion of community-based interventions, universal health coverage and the fostering of global partnerships. The laudable progress and benefits achieved are indispensable in championing, strengthening and moving forward elimination of the IDoPs. However, there is an urgent need for further innovative, contextual and integrated approaches along with the advent of the Sustainable Development Goals (SDGs), replacing the MDGs in ensuring global health security, well-being and economic prosperity for all.

Keywords: Nobel Prize, Artemisinin, Avermectin, Ivermectin, Praziquantel, Schistosomiasis, Intestinal helminths, Lymphatic filariasis, River blindness, Malaria, Discovery, Poverty

* Correspondence: tambo0711@gmail.com; ipdzhouxn@sh163.net
1Department of Biochemistry and Pharmaceutical Sciences, Higher Institute of Health Sciences, Université des Montagnes, Bangangté, Cameroon
2Public Health Pests Laboratory, Jeddah Municipality, Jeddah, Saudi Arabia
Full list of author information is available at the end of the article

© 2015 Tambo et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
This year’s Nobel Prize in Physiology or Medicine, awarded for the discovery of artemisinin and ivermectin, was divided between Youyou Tu "for her discoveries concerning a novel therapy against malaria" and William C. Campbell together with Satoshi Ōmura "for their discoveries concerning a novel therapy against roundworm infections" (Fig. 1). These parasitic infections have endangered human existence disproportionately, impeding productivity and economic growth due to major public health and societal burdens in developing and semi-industrialized countries in Sub-Saharan Africa, Southeast Asia and South America [1, 2]. For example, approximately 25 million people in Africa are still infected by onchocerciasis with more than 300,000 suffering from blindness, which explains the disease’s alternative name ‘river blindness’. It is estimated that the population at risk of just this one disease in the 31 endemic countries will be 250 million by 2016 [2, 3].

The burden of persisting and threatening infectious diseases in most developing countries is a complex affair, a fact recognized by The United Nations’ Millennium Development Goals (MDGs) [4] that represent one of the most successful anti-poverty movements ever undertaken. This 15-year effort to achieve eight goals, set out in the Millennium Declaration of the year 2000, has provided invaluable insights how governments, business and civil society can work together and achieve transformational breakthroughs in many areas, not the least in dealing with long-term, endemic diseases. Ours is a pivotal time for the international development sector with massive implications for global co-operation to control and eliminate endemic diseases and promote transformative social change to end poverty. The new 17 Sustainable Development Goals (SDGs) constitute a continuation and expansion of all aspects of the original eight MDGs and inclusion of neglected tropical disease (NTDs) in the Sustainable Development Goals. With respect to health, the MDG goal number 6 (to combat HIV/AIDS, malaria and other diseases) has been replaced by the SDG goal number 3 (to ensure healthy lives and promote well-being for all at all ages). Goal number one remains the same, i.e. to end poverty everywhere.

The root cause of the infectious diseases of poverty (IDoPs) is the ubiquitous presence of infectious agents. However, social and economic issues play a large role in their transmission and persistence, a fact recognized in both the MDGs and the follow-up SDGs. Still, the transformation of the endemic landscape is almost entirely due to large-scale distribution of the three novel ‘wonder drugs’ artemisinin, ivermectin and praziquantel, mainly used against malaria, lymphatic filariasis (LF)/river blindness and schistosomiasis, respectively. All three, discovered and developed in the 1970s (though extracts of the plant Artemisia - qinghaosu - has a long history in Chinese traditional medicine), are broad-spectrum drugs that can be used to cure many more infections than mentioned above; amazingly, the artemisinins have even effect against immature schistosomes, while ivermectin seems to limit the behaviour of the malaria vector. However, it was not evident that a new era had begun until the new drugs were in general use. Trying to pinpoint this historic shift exactly is of course futile, but
it can be said that after the large-scale introduction of modern chemotherapy in the 1980s and 1990s, the first decade of the new millennium marks the time that world-wide implementation of mass drug administration (MDA) occurred [9, 12]. Thanks to market price reductions and broad-scale interventions by international donor programmes, it did not take long until major endemic diseases had become manageable. Indeed, disease control programmes in the endemic countries were not only showing clear progress, but it was also possible to sustain the reduced morbidity and mortality achieved making it realistic to start planning for elimination of many of the endemic IDoPs, a momentous revolution [10, 12].

The discovery of artemisinin and ivermectin have had, and will continue to have, a long-lasting, strong impact on the IDoPs, the former due to its effect on the parasites causing malaria; the latter because its effect on the different nematodes that cause river blindness (Onchocerca volvulus), LF (Brugia and Wuchereria), hookworm infection (Ancylostoma, Necator) and other soil-transmitted helminthic (STH) infections [1–4]. With the presentation of a road map for the battle against the NTDs in January 2012, the World Health Organization (WHO) inspired the international community to engage into coordinated action involving policy-makers and implementers as well as international donors and the pharmaceutical industry [4]. While it was evident that many of these diseases could realistically be targeted for elimination, it was equally clear that novel drugs, sensitive diagnostics and sustainable approaches for effective surveillance and response together with effective and coordinated, preventive vector control programmes also must be in place [5, 6]. The new drugs, already developed, licensed and used for public health, have decisively demonstrated that malaria, river blindness and LF are preventable diseases whose control would particularly benefit the most vulnerable sectors of the endemic populations [4–8]. Progress has been achieved in all these areas, but greatest impact so far has been with respect to chemotherapy rather than vaccines that will be needed to complement chemotherapy in the longer perspective [7–10].

Youyou Tu’s landmark work, documented by increasing access to life-saving, effective artemisinin-based combination therapies (ACTs) against acute and severe malaria, intermittent preventive treatment and curative with respect also to the asexual plasmodium stages, has provided relief and hope for a large proportion of vulnerable populations in the endemic areas [9–11]. Importantly, in the face of increasing resistance of malaria parasites to 4-aminoquinolines (chloroquine) and antifolate drugs (sulphadoxine-pyrimethamine), thanks to the advent of the ACTs that the Global Malaria Action Plan (GMAP) managed to reduce malaria morbidity and mortality by 75 per cent in comparison to the situation in 2005, particularly among the poorest groups across all affected countries aggregate [12, 13]. Moreover, the new chemotherapy approach has made it possible to scale up national malaria control and elimination programmes enhancing interventions and universal health coverage to achieve WHO’s Roll Back Malaria (RBM) initiatives and those of the MDGs [13, 14]. For example, by the end of 2012, the United Nations Children’s Fund (UNICEF) had procured about 25 million ACTs treatments for 28 countries; however the proportion of children in sub-Saharan Africa with access to ACT is still variable and in many cases despairingly low (range <7 % to >90 % with the latter level only reached in a few countries) [10, 15, 16]. ACT is the drug of choice against acute and severe infection by Plasmodium falciparum and P. vivax, the most deadly malaria species, which are now resistant to chloroquine and antifolate drugs [10, 11, 16] in most endemic areas. Hence the call for innovative and integrated community-based packages [16, 17] in strengthening implementation and management has executed by the Malaria Eradication Research Agenda (malERA) and the Malaria Eradication Scientific Alliance (MESA) in the most highly endemic developing and semi-industrialized countries [18].

Both acute and severe malaria continues to exert a deep-rooted impact in 109 countries and territories around the world and still constitute a leading risk factor for infant mortality and sub-optimal growth and development in spite of the global malaria elimination campaign programmes (GMECPs) that were in effect in the 1950s to the 1970s [10, 19]. By 2000, there was an estimated 350–500 million cases of malaria and more than one million deaths, most of them in children under 5 years, pregnant women and non-immune travelers in Africa and Asia-Pacific [19]. The saying “One child dying of malaria every second” remains true to this day, and the disease still has a serious economic impact in Africa, retarding economic growth and development and perpetuating the vicious cycle of poverty [15, 18–20].

In 1971, at the Pharmaceutical Institute of the Academy of Traditional Chinese Medicine, Youyou Tu showed that Artemisia plant extracts could kill P. berghei, a rodent malaria parasite laboratory model. The following year, she succeeded in isolating the active ingredient (qinghaosu), now part of ACT, the most important class of anti-malaria medications [9, 20, 21]. Artemisinin derivatives are postulated to act by inhibiting the major metabolic processes of the malaria parasite, such as glycolysis, nucleic acid and protein synthesis, thus exercising a broad-based activity extending to impeding the development of gametocytes that promises future development of transmission-blocking, sexual-stage drugs and vaccine discovery
Still, years after the original discovery of the drug, the complete mechanism of artemisinin is not fully elucidated, though recent evidence suggest that is based on the activity of 13 proteins, some of which showed to be involved in the emergence of resistance in Southeast Asia, e.g. the Thai-Cambodia borders areas [24]. Impressive progress has been achieved in product development, manufacturing, procurement as well as financial accessibility to treatment (the latter regarding the ACTs in particular) even if prompt, affordable and widespread coverage is still not achieved in many public health facilities in remote, hard-to-reach endemic settings [12, 24, 25]. From 2004 to 2006, the annual global procurement of ACT increased from 4 million to ~100 million doses (~125 million doses in 2007), around 70 % of which were used in Africa, resulting in a significant reduction of morbidity and mortality in children and trimmed-down numbers of acute and severe cases of malaria overall [12, 14, 25, 26].

The latest decades have witnessed substantial progress in raising awareness and increasing the production, adoption and distribution of existing effective interventions besides the use of ACTs, e.g. indoor residual spraying (IRS) and large-scale distribution of long-lasting insecticidal nets (LLINs) as prescribed by the RBM’s universal coverage partnership [12, 27, 28]. The latest available worldwide report of malaria cases concerns the year 2013, in which WHO reports that about 3.2 billion people are at risk of this infection with more than 132 million confirmed cases; however, the real level of incidence must be higher since the number of suspected cases has surpassed 367 million [29]. Africa still has the heaviest burden with children less than 5 years old making up 90 % of the malaria-related deaths, which accounts for 78 % of the total mortality [29, 30]. In addition to the high local healthcare burden in Africa, malaria illness and mortality affect crop production and decrease tourism, which is estimated to cost approximately USD12 billion each year due to increased school and work absenteeism, lost productivity and constraints to foreign investment [10, 30]. Hence, although the impact of malaria in the endemic countries has abated to some extent in some areas, transmission continues at a high level assuring that the global ACTs demand will remain robust over the coming years as treatment-adherence and compliance remain vital in the struggle to substantially reduce malaria morbidity and mortality supporting the hope of eventually reaching sustained control, elimination and subsequent eradication of the disease [29, 31].

William C. Campbell and Satoshi Ōmura discoveries proved to be a breakthrough in the tenacious fight against infections caused by roundworm parasites, mainly onchocerciasis and LF, dreaded health scourges of the most vulnerable groups of affected populations. The discovery, industrial development and implementation of the active avermectin derivative ivermectin (best known under the brand name Mectizan) led to a significant reduction of onchocerciasis in the endemic areas in central Africa and Latin America as well as of LF and scabies that are also endemic in India and Southeast Asia, thus improving the situation in vulnerable communities in low- and middle-income countries (LIMCs) [1, 3]. In an unusual move, the manufacturer of ivermectin, Merck & Co., Inc. declared it would donate ivermectin free of charge for as long as it would be needed through its Mectizan Donation Program, which works with governments (Ministries of Health) and various partners with national onchocerciasis control programmes to scale up distribution and coverage of the drug locally [9, 32]. Its impact on mosquito control in malaria is debatable and the drug is not donated for this purpose.

Onchocerciasis, transmitted by the filarial worm *O. volvulus*, is transmitted to humans through bites of infected female blackflies (*Simulium* spp.). Adult worms can live up to 18 years in infected human hosts and release up to 1,000 microfilariae daily causing a variety of ailments including skin lesions due to chronic dermatitis, rashes, intense itching, depigmentation as well as visual impairment due to eye inflammation causing corneal scars eventually leading to irreversible blindness [3, 32]. The disease is endemic in 35 countries, including 28 African countries, Yemen in the Middle East and six Latin American countries resulting in an estimated 17.7 million people infected, approximately 500,000 with visual impairment, 270,000 of whom are blind; about 99 % of all cases, however, are found in Africa according to WHO [2, 32, 33]. The Onchocerciasis Control Programme (OCP) operated in West Africa from 1974 to 2002 [2–33] and its work is being continued by the larger African Programme for Onchocerciasis Control (APOC) that coordinates annual community-wide treatment regimens with ivermectin in 16 countries. An estimated 8.2 million disability-adjusted life years (DALYs) [4, 13] at a nominal cost of about USD257 million was averted between 1995 and 2010 and APOC estimates to have warded off another 9.2 million DALYs between 2011 and 2015 at a nominal cost of USD 221 million [2, 4]. Interventions in countries in West Africa employed large-scale, community-directed treatment with ivermectin (CDTI) and ONCHOSIM, a computer-based software developed to model the transmission and control of onchocerciasis allowing the continuous annual treatment of more than 30 million people [34]. As of 2012, over 200 million people have received ivermectin; 118 million a combination of ivermectin and
Ivermectin is provided as MDA once or twice annually to millions of the most vulnerable children and adults populations in most LMICs. The current WHO chemotherapy-based strategy controls the morbidity in poor and marginalized communities in conjunction with interventions against cestode and nematode infections with albendazole and ivermectin. Severe morbidity due to schistosomiasis can be prevented by regular treatment of risk groups targeted based on community diagnosis at sentinel sites. Like malaria, LF and river blindness, schistosomiasis is prevalent in tropical and sub-tropical areas, in poor communities without potable water and adequate sanitation. Like the other infections discussed here, schistosomiasis is one of IDoPs. It affects about 240 million people worldwide, and more than 700 million people live in endemic areas. In contrast to FBT infections, cysticercosis and echinococcosis, there has been strong progress on the schistosomiasis agenda, mainly thanks to long-term, national control programmes that in some countries, notably Brazil, China and Egypt, have been highly successful in driving prevalence and morbidity down. In 2013, more than 39 million people were treated for this disease with praziquantel. However, this represents only about 13 % of the population requiring treatment globally.

The global IDoP elimination agenda will require strengthening community, national and regional leadership and commitment to rapidly increase funding and fostering integrated multidisciplinary and inter-sectorial policies. Furthermore, scaling-up of high-impact MDA coverage of available drugs, development and implementation of new, effective vaccines and other novel approaches and tools are needed in addressing the geographical complexity of the panoply of different diseases including malaria, river
blindness, LF and schistosomiasis [56, 57]. This would mean enlarging the use of geographical information systems (GIS) and other advanced cutting-edge technologies for general surveillance and monitoring, including risk mapping of vector and parasite hotspots and studying reservoir resurgence and drug resistance. Improving local and cross-border malaria early-warning signals and surveillance systems is imperative in providing new information on potential epidemiologic transitions, crucial for quick response to any potential resurgence of vector density and competence potentially leading to disease outbreaks. These approaches will contribute to new evidence-based information needed in adapting effective health financing and programming to effective local and national programmes and interventions. Hence, consolidating and refining the laudable gains and lessons learnt from cost-effective therapeutic discoveries should contribute to the continuous pharmacovigilance associated with adverse reactions (ADR) of existing therapies leading to improved access to quality care services, procurement and supply of quality medicines and supplies needed in boosting the momentum of the elimination of IDoP.

The pharmacological and therapeutic paradigm shift discussed here calls for further, strong investments in research and development in the field of drugs and vaccines creating pipelines of new products capable of tackling the challenge of rapid emergence and spread of vectors, parasites and drug resistance. Timely, evidence-based and cost-effective operational approaches and solutions for IDoPs and NTDs are required for dealing with the rise and spread of insecticide resistance, and the environmental impact of climate change. Likewise, development of diagnostics with improved sensitivity and specificity as well as preventive therapeutics and efficient information communication/dissemination mechanisms underscore the quest for novel and innovative approaches. Leveraging on lessons learnt, efficient and integrated intersectoral partnerships as well as collaboration in the development of needed, new diagnostics, drugs and vaccines are much needed. So are also proven and innovative community-based programmes with respect to ownership in health systems, surveillance and new opportunities in elimination interventions packages and eventually in moving forward eradication of IDoP worldwide.

Abbreviations
IDoP: Infectious Diseases of Poverty; ACT: Artemisinin Combination Therapy; ComDT: Community Directed Treatment; SDGs: Sustainable Development Goals; MDGs: Millennium Development Goals; LMICs: Low and Middle Income Countries; GMAP: Global Malaria Action Plan; GMCP: Global Malaria Eradication Campaign programs; OPEA: Onchocerciasis Elimination Program of the Americas; PAHO: Pan American Health Organization; RBM: Roll Back Malaria; PRDs: Poverty-related diseases; NIDs: Neglected infectious diseases; MDA: Mass drug administration; APOC: African Programme for Onchocerciasis Control; DALYs: Disability adjusted-life years; maIERA: Malaria Eradication Research Agenda; MESA: Malaria Elimination Scientific Alliance; UNICEF: United Nations Children Emergency Funds; WHO: World Health Organization; TDR: Tropical Diseases Research.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
ET conceived, performed the literature search, analyzed and wrote the primary draft of the manuscript. ET, EIK, JHC, RB and ZXN provided additional evidence and experts insights. All authors read and approved the final version of the manuscript.

Acknowledgment
We are grateful of the funding support received from National Institute of Parasitic Diseases, China, Chinese Center for Disease and Prevention, Shanghai on this project, through China-UK Global Health Support Programme (GHSP OP302).

Author details
1Department of Biochemistry and Pharmaceutical Sciences, Higher Institute of Health Sciences, Université des Montagnes, Bangangté, Cameroon. 2Sydney Brenner Institute for Molecular Biosciences, University of the Witwatersrand, Johannesburg, South Africa. 3Africa Disease Intelligence and Surveillance, Communication and Response Foundation (Africa DISCoR), Yaoundé, Cameroon. *Center for Sustainable Malaria Control, Department of Biochemistry, Faculty of Natural and Agricultural Sciences, University of Pretoria, Pretoria, South Africa. 4Public Health Pests Laboratory, Jeddah Municipality, Jeddah, Saudi Arabia. 5Department of Entomology, Faculty of Science, Ain Shams University, Cairo, Egypt. 6National Institute of Parasitic Diseases, Chinese Center for Disease Control and Prevention, Shanghai 200025, P.R. China. 7Key Laboratory of Parasite and Vector Biology of the Chinese Ministry of Health, Shanghai 200025, P.R. China. 8WHO Collaborating Centre for Tropical Diseases, Shanghai 200025, P.R. China. 9Ringerod, Brastad, Sweden.

Received: 5 November 2015 Accepted: 10 December 2015
Published online: 28 December 2015

References
1. World Health Organization (WHO) 2013. Program for the elimination of neglected diseases in Africa (PENDA). 2016–2025. Accessed on 15 Oct 2015
2. WHO. Global technical strategy for malaria 2016–2030. 2015; ISBN 978 92 4 156499. http://apps.who.int/iris/bitstream/10665/176712/1/9789241564991_eng.pdf?ua=1&ua=1. accessed on 15th October 2015.
3. WHO. APOC strategic plan. www.who.int/apoc/en/apoc_strategic_plan_2013.pdf, accessed 15 October 2015.
4. Boatin B. The Onchocerciasis Control Programme in West Africa (OCF). Ann Trop Med Parasitol. 2008;102 Suppl 1:13–7.
5. WHO. Accelerating work to overcome the global impact of neglected tropical diseases. A roadmap for implementation (http://www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf) accessed 24 October 2015.
6. Tu Y. The development of the antimalarial drugs with new type of chemical structure: Qinghaosu and Dihydro Qinghaosu. Southeast Asian J Trop Med Public Health. 2004;35:250–1.
7. Yu Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med. 2011;17(10):1217–20. doi:10.1038/nm.2471.
8. Su ZX, Miller LH. The discovery of artemisinin and the Nobel Prize in Physiology or Medicine. Sci China Life Sci. 2015 Oct 19. [Epub ahead of print].
9. Campbell WC. The genesis of the antiparasitic drug ivermectin. In: Weber RJ, Perkins DN, editors. Inventive Minds. New York: Oxford University Press; 1992. p. 194–214.
10. David H, Molyneux, Steve A. Ward. Reflections on the Nobel Prize for Medicine 2015 – The Public Health Legacy and Impact of Avermectin and Artesunate. Trends in Parasitology. 2015 Vol 31; Available online 6 November 2015 in Press.
11. Owens B. Nobel Prize goes to antiparasitic drug discoverers. Lancet. 2015;386(10002):1433. doi:10.1016/S0140-6736(15)00455-9.
12. Ōmura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents. 2008;31:91–8.
early parasitological response to the effects of individual patient data. BMC Med. Author manuscript; available in PMC 2015 August 6.

20. The malERA Consultative Group on Monitoring, Evaluation, and Surveillance. A Research Agenda for Malaria Eradication: Monitoring, Evaluation, and Surveillance. PLoS Med. 2011;8(10):e1000400. doi:10.1371/journal.pmed.1000400. Published online 2011 January 25.

21. Jonne M, Yoeli L, Kara H. Malaria eradication: the economic, financial and institutional challenge. Malar J. 2008;7 Suppl 1:S11. doi:10.1186/1475-2875-7-S1-S11. Published online 2008 December 11.

22. Xia ZG, Wang RB, Wang DQ, Feng J, Zheng Q, Deng CS, et al. China-Africa cooperation initiatives in malaria control and elimination. Adv Parasitol. 2014;86:139–178. doi:10.1016/B978-0-12-800869-0.00012-3.

23. C-ORGo Q. Antimalaria studies on Qinghaosu. Chin Med J (Engl). 1979;92:811–813.

24. Julie T, Eisele TP, Steketee RW. Protective efficacy of malaria case management for preventing malaria mortality in children: a systematic review for the Lives Saved Tool. BMC Public Health. 2011;11 Suppl 3:S1. doi:10.1186/1471-2458-11-S3-S14. Published online 2011 April 13.

25. Janette R, Mariëtte B, Anjo T, Lauterbach SB, Claire R, Dewaldt E, et al. Large-Scale Preventive Chemotherapy for the Control of Malaria Infection in Western Pacific Countries: Six Years Later. PLoS Negl Trop Dis. 2011;5(9):e56740.

26. Whitty CJM, Clare C, Evelyn A, Toby L, Staeedie SG. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J. 2008;7 Suppl 1:S7.

27. Shah JA, Erina MB, Eckert E, Ye Y. Prompt access to effective malaria treatment among children under five in sub-Saharan Africa: a multi-country analysis of national household survey data. Malar J. 2015;14:329.

28. Somwunni A, Fateye BA, Adejite AA, Fehintola FA, Gbotosho GO, Happi TC, et al. Predictors of chloroquine or pyrimethamine-sulfadoxine treatment failure in children with acute uncomplicated falciparum malaria. An Trop Med and Parasitol. 2005;56:355–363.

29. WWARN Artemisinin based Combination Therapy (ACT) Africa Baseline research for innovation in designing interventions. Malar J. 2015;14:279.

30. Liese BH, Schubert L. Official development assistance for health—how neglected are neglected tropical diseases? An analysis of health financing. International Health. 2009;11:141–147.

31. Antoine T, Fisher N, Amewu R, O'Neill PM, Ward SA, Biagini GA. Rapid kill of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci U S A. 2013;110(1):240–245. doi:10.1073/pnas.1217772110. Published online 2012 December 17.

32. Chaccour CJ, Kobilinsky KC, Quique B, Teun B, Chris D, Pedro A, et al. Ivermectin to reduce malaria transmission: a research agenda for a promising new tool for elimination. Malar J. 2013;12:153.

33. Oliver S, Cohen JM, Karim MS, Kahn JG, Suputtith S, Linhua T, et al. Costs and financial feasibility of malaria elimination. Lancet. 2010;376(9752):1604–1605.

34. Whitty CJM, Clare C, Evelyn A, Toby L, Staeedie SG. Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J. 2008;7 Suppl 1:S7.

35. Gustavsen KM, Bradley MH, Wright AL. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis. Ann Trop Med Parasitol. 2009;103 Suppl 1:S1–S5.

36. World Health Organization. Report of the sixth meeting of the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases. WHO Headquarters, Geneva. Geneva World Health Organization; 2013. Available: http://www.who.int/neglected_diseases/NTD_STAG_Report_2013.pdf. Accessed 14 October, 2015.

37. Ramaiah KD, Ottesen EA. Progress and Impact of 13 Years of the Global Programme to Eliminate Lymphatic Filariasis on Reducing the Burden of Filarial Disease. PLoS Negl Trop Dis. 2014;8(11):e3319. doi:10.1371/journal.pntd.0003319.

38. Liese BH, Schubert L. Official development assistance for health—how neglected are neglected tropical diseases? An analysis of health financing. International Health. 2009;11:141–147.

39. Montresor A, Dai Tran C, Mouth S, Reko T, Chitsungo C, Hanne S, et al. Large-scale Preventive Chemotherapy for the Control of Helminth Infection in Western Pacific Countries: Six Years Later. PLoS Negl Trop Dis. 2009;3(8):e278.

40. Turner HC, Walker MJ, Chuchter TS, Osei-Atweneboana MY, Britwum N-K, Hopkins A, et al. Reaching the London Declaration on Neglected Tropical Diseases Goals for Onchocerciasis: An Economic Evaluation of Increasing the Frequency of Ivermectin Treatment in Africa. Clin Infect Dis. 2014;59(7):923–932.

41. Ken G, Adrian H, Mauricio S. Onchocerciasis in the Americas: from arrival to eradication. Parasit Vectors. 2011;4:205.

42. Ichimori K, King JD, Engels D, Yajima A, Mikhallov A, Lammie P, et al. Global Programme to Eliminate Lymphatic Filariasis: The Processes Underlying Programme Success. PLoS Negl Trop Dis. 2014;8(12):e3328.

43. Haques A, Kajacic BJ, Meyers J, Grubaugh ND, Brackney DE, Kobylynski KC, et al. Evaluation of ivermectin mass drug administration for malaria transmission control across different West African environments. Malar J. 2014;13:417.

44. Nörenberg W, Sobotka H, Hempel C, Plötz T, Fischer W, Schmalzing G, et al. Positive allosteric modulation by ivermectin of human but not murine 2p7 receptors. Br J Pharmacol. 2012;167(1):48–66.

45. Diawara L, Traore MO, Badji A, Bissan Y, Doumbia K, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis. 2009;3(4):497.

46. Turner HC, Osei-Atweneboana MY, Walker MJ, Tettei EV, Chuchter TS, Asiedu O, et al. The Cost of Annual versus Biannual Community-Directed Treatment of Onchocerciasis with Ivermectin: Ghana as a Case Study. PLoS Negl Trop Dis. 2013;7(19):e2452.

47. World Malaria Day 2015. Community-Based Approaches to Save Women and Children. http://www.msh.org/blog/2015/04/24/world-malaria-day-2015-three-community-based-approaches-to-save-women-and-children accessed on 18th October 2015.

48. Mcmahon JE, Kolstrup N. Praziquantel: a new schistosomicide against Schistosoma haematobium. Br Med J. 1979;2(6202):1396–8.

49. Evans D, Mcfarland D, Adami W, Egige A, Mii E, Schulz J, et al. Cost-effectiveness of triple drug administration (TDA) with praziquantel, ivermectin and albendazole for the prevention of neglected tropical diseases in Nigeria. Ann Trop Med Parasitol. 2011;105(8):537–47.

50. Meredith SEO, Catherine C, Aramuzo UV. Empowering communities in combating river blindness and the role of NGOs: case studies from Cameroon, Mali, Nigeria, and Uganda. Health Res Policy Syst. 2012;10:16. doi:10.1186/1478-4505-10-16. Published online 2012 May 10.

51. Linehan M, Hanson C, Weaver A, Baker M, Kabore A, et al. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale. Amer J Trop Med Hyg. 2011;84:845–9.

52. Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme H, et al. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis. 1995;172:5.

53. Panic C, Vargas M, Scandale I, Keiser J. Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9(7):e0003962.

54. WHO, Food borne trematodiases. Factsheet. http://www.who.int/mediacentre/factsheets/fs568/en/ (accessed 30 October 2015)
55. WHO. Schistosomiasis: A major public health problem. http://www.who.int/schistosomiasis/en/ (accessed 30 October 2015)
56. WHO. Foodborne trematode infections. http://www.who.int/foodborne_trematode_infections/en/ (accessed 30 October 2015)
57. Russell Stothard J, Sousa-Figueiredo JC, Betson M, Bustinduy A, Reinhard-Rupp J. Schistosomiasis in African infants and preschool children: let them now be treated. Trends Parasitol. 2013;29(4):197–205.